Yazar "Arsava, Ethem Murat" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study
    (Galenos Publ House, 2023) Topcuoglu, Mehmet Akif; Ozdemir, Atilla Ozcan; Arsava, Ethem Murat; Gunes, Aygul; Aykac, Özlem; Gencer, Elif Sarionder; Cabalar, Murat
    Objective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neurointerventional therapy in Turkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0-2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 +/- 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 +/- 6; hospital stay, 24 +/- 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 +/- 13 years; NIHSS: 14.1 +/- 6.5; length of hospital stay, 33 +/- 31 days), 19% in those who received combined treatment (age: 66 +/- 14 years; NIHSS: 15.6 +/- 5.4; length of hospital stay, 26 +/- 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 +/- 13 years; NIHSS: 7.6 +/- 7.2; length of hospital stay, 21 +/- 28 days). The symptom-to-door time was 87 +/- 53 minutes in the IV treatment group and 200 +/- 26 minutes in the neurointerventional group. The average door-to-needle time was 66 +/- 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 +/- 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0-2 was 41%, while the rate of mRS 0-1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0-2 was 31% and mRS 0-1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 +/- 107 and 95 +/- 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the hemorrhage rate was 6.8% in patients receiving IV tPA and 16.9% in MT. Conclusion: IV thrombolytic and neurointerventional treatment applications in acute ischemic stroke in Turkiye can provide the anticipated results. Heterogeneity has begun to be reduced in our country with the dissemination of the system indicated by the Directive on Health Services to be Provided to Patients with Acute Stroke.
  • [ X ]
    Öğe
    Atrial Fibrillation Management in Acute Stroke Patients in Türkiye: Real-life Data from the NöroTek Study
    (Galenos Publ House, 2023) Topcuoglu, Mehmet Akif; Arsava, Ethem Murat; Ozdemir, Atilla Ozcan; Aykac, Ozlem; Cetiner, Mustafa; Gencer, Elif Sarioender; Gunes, Aygul
    Objective: Atrial fibrillation (AF) is the most common directly preventable cause of ischemic stroke. There is no dependable neurology-based data on the spectrum of stroke caused by AF in Turkiye. Within the scope of NoroTek-Turkiye (TR), hospital-based data on acute stroke patients with AF were collected to contribute to the creation of acute-stroke algorithms.Materials and Methods: On May 10, 2018 (World Stroke Awareness Day), 1,790 patients hospitalized at 87 neurology units in 30 health regions were prospectively evaluated. A total of 929 patients [859 acute ischemic stroke, 70 transient ischemic attack (TIA)] from this study were included in this analysis.Results: The rate of AF in patients hospitalized for ischemic stroke/TIA was 29.8%, of which 65% were known before stroke, 5% were paroxysmal, and 30% were diagnosed after hospital admission. The proportion of patients with AF who received effective treatment [international normalization ratio >= 2.0 warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) at a guideline dose] was 25.3%, and, either no medication or only antiplatelet was used in 42.5% of the cases. The low dose rate was 50% in 42 patients who had a stroke while taking NOACs. Anticoagulant was prescribed to the patient at discharge at a rate of 94.6%; low molecular weight or unfractionated heparin was prescribed in 28.1%, warfarin in 32.5%, and NOACs in 31%. The dose was in the low category in 22% of the cases discharged with NOACs, and half of the cases, who received NOACs at admission, were discharged with the same drug.Conclusion: NoroTekTR revealed the high but expected frequency of AF in acute stroke in Turkiye, as well as the aspects that could be improved in the management of secondary prophylaxis. AF is found in approximately one-third of hospitalized acute stroke cases in Turkiye. Effective anticoagulant therapy was not used in three-quarters of acute stroke cases with known AF. In AF, heparin, warfarin, and NOACs are planned at a similar frequency (one-third) within the scope of stroke secondary prophylaxis, and the prescribed NOAC dose is subtherapeutic in a quarter of the cases. Non-medical and medical education appears necessary to prevent stroke caused by AF.
  • Küçük Resim
    Öğe
    The COVID-19 from neurological overview
    (Turkish Neurosurgical Society, 2020) Acar, Türkan Atılgan; Demirel, Esra Acıman; Afşar, Nazire; Akçal, Aylin; Demir, Gülşen Akman; Alagöz, Aybala Neslihan; Mengi, Tuğçe Angın; Arsava, Ethem Murat; Ayta, Semih; Bebek, Nerses; Bilgiç, Başar Gar; Boz, Cavit; Çakar, Arman; Çelebisoy, Neşe; Çevik, Mehmet Uǧur; Delen, Firuze; Tekçe, Hacer Durmuş; Ekmekçi, Hakan Ahmet; Elmal, Ayşe Deniz; Erdinç, Oǧuz Osman; Erdoǧan, Füsun Ferda; Eren, Fettah; Ergün, Ufuk; Parman, Yeşim Gülşen; Gümüş, Haluk; Algn, Demet İlhan; Karabudak, Rana; Karada̧s, Ömer; Yıldız, Özlem Kayım; Koç, Emine Rabia; Adapnar, Demet Özbabalk; Özdemir, Atilla Özcan; Öztürk, Şerefnur; Kocaman, Ayşe Saǧduyu; Sahin, Sevki; Topçuoğlu, Esen Saka; Şener, Özden; Tezer, Fadime İrsel; Toğrol, Rıfat Erdem; Tokçaer, Ayşe Bora; Topçuoǧlu, Mehmet Akif; Tuncer, Neşe; Uca, Ali Ulvi; Uluç, K.; Yaka, Erdem; Yön, Mehmet İlker
    Since December 2019, the disease caused by a new type of coronavirus called “New Coronavirus Disease (COVID-19)” has spread rapidly from Wuhan to other provinces of the Republic of China, and then to the entire world (1). With this pandemic around the world and in Turkey, very strong and shocking changes occurred in the flow of life, lifestyle, habits, education, politics, and the economy. Many issues related to COVID-19 have been discussed in the media, mostly new faces, new opinions, new expressions, mostly of scientists and physicians who have rarely been seen before have started to appear in media. With this fast-developing situation threatening the existence of all humanity, the perception of life, today and the future, has differentiated, and death has been considered more than ever before. In this process, new terms and concepts, which have never been used before or used very little, have started to be used frequently
  • [ X ]
    Öğe
    İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ
    (2020) Ünal, Ali; Eren, Alper; Yıldız, Özlem Kayım; Yaka, Erdem; Öztürk, Vesile; Özdemir, Atilla Özcan; Arsava, Ethem Murat
    Non-vitamin K oral antikoagülanların (NOAK) atrial fibrilasyonda inmenin önlenmesi amacıyla on yılı aşan bir süredir başarı ile kullanıldığı açıktır. Varfarine göre belirgin derecede az kanamaya yol açmaları ve inmeyi de eşit veya daha fazla oranda önleyebilmeleri yanı sıra kolay kullanım özellikleri primer proflakside atrial fibrilasyona bağlı inmeyi azaltma konusunda öne çıkmaktadır. Bunlar aynı zamanda genel inme prevalansının azalması anlamına gelmektedir. Yani AF nedenli inmenin engellenmesi toplum sağlığı için çağdaş bir gereklilik olarak algılanmalıdır. İnme klinik pratiğinde kardiyoloji uzmanları ile birlikte bu bağlamda çaba sarf eden nöroloji uzmanları için Türk Beyin Damar Hastalıkları Derneği bu uzman görüşünü hazırladı. Görüşler NOAK grubu ilaçların kullanımında sıkça karşılaşılan sorunlar ve bu problemler için güncel çözüm önerilerini içermektedir.